Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DSM39E
|
|||
| Drug Name |
CCI 15106
|
|||
| Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J40-J44, J47; ICD-9: 490-492, 494-496] | Phase 1 | [1] | |
| Company |
GlaxoSmithKline
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03235726) A Double-blind (Sponsor Unblind), Randomized, Placebo-controlled, Single and Repeat Escalating Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CCI15106 Inhalation Powder in Healthy Participants and Participants With Moderate Chronic Obstructive Pulmonary Disease (COPD) Including Evaluation of Environmental and Healthy By-stander Exposure Levels During Dosing. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.